What are the statistics for Alzheimer’s disease in the United States?

- Alzheimer’s disease is one of the top 10 leading causes of death in the United States.²
- The 6th leading cause of death among US adults.
- The 5th leading cause of death among adults aged 65 years or older.³
- In 2020, an estimated 5.8 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060.
- In 2010, the costs of treating Alzheimer’s disease were projected to fall between $159 and $215 billion.
- By 2040, these costs are projected to jump to between $379 and more than $500 billion annually.
- Death rates for Alzheimer’s disease are increasing, unlike heart disease and cancer death rates that are on the decline. Dementia, including Alzheimer’s disease, has been shown to be under-reported in death certificates and therefore the proportion of older people who die from Alzheimer’s may be considerably higher.

Advanced Targeting Systems has research tools to advance the study of Alzheimer’s Disease.

TARGETED TOXINS

192-IgG-SAP – targets cells expressing LNGFR in rat [Cat. #IT-01]
mu p75-SAP – targets cells expressing LNGFR in mouse [Cat. #IT-16]
ME20.4-SAP – targets cells expressing LNGFR in various species [Cat. #IT-15]
Anti-ChAT-SAP – targets cells expressing choline acetyltransferase [Cat. #IT-42]
Anti-DBH-SAP – targets cells expressing dopamine beta-hydroxylase [Cat. #IT-03]

ANTIBODIES

NGFr (mu p75) Rabbit Polyclonal [Cat. #AB-N01; AB-N01AP]
NGFr (mu p75) Rabbit Polyclonal, Alexa488-labeled affinity-purified [Cat. #FL-N01AP]
NGFr (mu p75) Rabbit Polyclonal, Cy3-labeled affinity-purified [Cat. #FL-05]
NGFr (mu p75) Rabbit Polyclonal, Cy5-labeled affinity-purified [Cat. #FL-06]
Choline Acetyltransferase Rabbit Polyclonal, affinity-purified [Cat. #AB-N34; AB-N34AP]
Nicotinic Acetylcholine Receptor alpha 1 (mAb 35) Rat Monoclonal [Cat. #AB-N36]
NGFr (192-IgG, p75) Mouse Monoclonal [Cat. #AB-N43]

Advanced Targeting Systems

www.ATSbio.com